A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates
about
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesPoxvirus vectors as HIV/AIDS vaccines in humansEvaluation of in vitro cross-reactivity to avian H5N1 and pandemic H1N1 2009 influenza following prime boost regimens of seasonal influenza vaccination in healthy human subjects: a randomised trialExploring peptide mimics for the production of antibodies against discontinuous protein epitopes.Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines.Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes.Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa.Evidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaquesImmune-based therapies: a review of clinical endpoints used in trials of selected immunologic agents.Effect of the V3 loop deletion of envelope glycoprotein on cellular responses and protection against challenge with recombinant vaccinia virus expressing gp160 of primary human immunodeficiency virus type 1 isolates.Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins.Neutralizing antibodies to HIV-1 induced by immunization.Human immunodeficiency virus type 1 primary isolate neutralization resistance is associated with the syncytium-inducing phenotype and lower CD4 cell counts in subtype CRF01_AE-infected patients.
P2860
Q24561905-112353E4-8738-415A-B975-1471C5ABE604Q26995078-43C03569-E3FE-408D-A2C1-1C05B91839FCQ30429009-A22717C0-AC05-4B78-A867-371A130E9468Q33520582-E660372C-A01C-44E2-8949-1E215276E707Q33780524-DC8DAD8E-2805-4F12-9000-A09A27889E77Q33787329-9AE99D7A-3576-4C59-8D48-384E4283FE87Q34145199-6B9D3D95-7CDC-4F85-9F77-E74F9812AF39Q34229329-4D73FC3C-90F7-4FB3-B69C-B0B6776824A2Q34462167-4D6905FA-5336-48CA-97E2-80510FC758CAQ34511936-25105DE7-577E-452C-A092-232D3F851185Q34999946-C3890DB6-3BC5-4E59-BAA8-38D2365122DFQ36424523-DDBA6731-4A07-4CE9-B32B-E426CFFB4DB2Q36603515-C19E9D89-E29B-46F5-8A84-068AC0DEEA35Q39789278-2AD7BEF7-9BEB-41DA-8763-6F8494A09473
P2860
A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
A human immunodeficiency virus ...... clade B and C primary isolates
@ast
A human immunodeficiency virus ...... clade B and C primary isolates
@en
type
label
A human immunodeficiency virus ...... clade B and C primary isolates
@ast
A human immunodeficiency virus ...... clade B and C primary isolates
@en
prefLabel
A human immunodeficiency virus ...... clade B and C primary isolates
@ast
A human immunodeficiency virus ...... clade B and C primary isolates
@en
P2093
P2860
P1433
P1476
A human immunodeficiency virus ...... clade B and C primary isolates
@en
P2093
A M Duliege
J L Excler
S Zolla-Pazner
P2860
P304
10025-10033
P356
10.1128/JVI.74.21.10025-10033.2000
P577
2000-11-01T00:00:00Z